reference/7413411

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/7413411

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase II\|Journal Article\|Multicenter Study\|Randomized Controlled Trial\|Research Support, Non-U.S. Gov't
endingPage	411
issn	1875-8908 1387-2877
issueIdentifier	2
pageRange	401-411
publicationName	Journal of Alzheimer's disease : JAD
startingPage	401
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_448c3d7a8b95445db230c0de0b6d375a http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_916de93fe8f49855f42e16db43537393
isSupportedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_405dd068620eec701ee6f41273ac4e80 http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_04da603518dc3d6aae494967c7acdbe9 http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_91ff89b21fa9b5bd17a52667d9b17ad6
bibliographicCitation	Rafii MS, Skotko BG, McDonough ME, Pulsifer M, Evans C, Doran E, Muranevici G, Kesslak P, Abushakra S, Lott IT; ELND005-DS Study Group. A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Oral ELND005 (scyllo-Inositol) in Young Adults with Down Syndrome without Dementia. J Alzheimers Dis. 2017;58(2):401–11. PMID: 28453471; PMCID: PMC5777855.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_78df6d9dd8f705f3e26db8a71c794412 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7700908566e1c75cb28024a2f7a0d53e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8bc4153da76bd9006a5310c99f2cc7f6 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7fae6606926393e7e2fb0f28d8467e46 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_159b411e81a21d9e27331326bbc0ecc8 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d6b0561ca45f44b32c5934915d37aee6 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3ef73ad44207e5374dff758d72920385 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0704f40a34cd33e807d4215e4b6fa856 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8e01194b782c0b1585cd7313c0cc3e94 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_12f6063d0cf22c4abfb0a21ccf7d6c60
date	2017-05-11-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/PMC5777855 https://doi.org/10.3233/jad-160965 https://pubmed.ncbi.nlm.nih.gov/28453471
isPartOf	https://portal.issn.org/resource/ISSN/1875-8908 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/21942 https://portal.issn.org/resource/ISSN/1387-2877
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Oral ELND005 (scyllo-Inositol) in Young Adults with Down Syndrome without Dementia
discusses	http://id.nlm.nih.gov/mesh/M0053732 http://id.nlm.nih.gov/mesh/M0011374
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D007294Q000008 http://id.nlm.nih.gov/mesh/D004314Q000188
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D004314Q000150 http://id.nlm.nih.gov/mesh/D004311 http://id.nlm.nih.gov/mesh/D016896 http://id.nlm.nih.gov/mesh/D004562 http://id.nlm.nih.gov/mesh/D000284 http://id.nlm.nih.gov/mesh/D055815 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D000328 http://id.nlm.nih.gov/mesh/D007294Q000493 http://id.nlm.nih.gov/mesh/D001523Q000209 http://id.nlm.nih.gov/mesh/D011569 http://id.nlm.nih.gov/mesh/D000293 http://id.nlm.nih.gov/mesh/D003072Q000209 http://id.nlm.nih.gov/mesh/D008279 http://id.nlm.nih.gov/mesh/D004314Q000000981 http://id.nlm.nih.gov/mesh/D011446
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7404 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7488 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6852 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID892

Total number of triples: 61.